Evidence map›Paper›PMID 29680581›Full record

ReviewThe Lancet. Infectious diseases2018

Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission.

David S Hui, Esam I Azhar, Yae-Jean Kim, Ziad A Memish, Myoung-Don Oh, Alimuddin Zumla

2 registry-linked trialsOpen access · bronzeAbstract readReview
In one paragraph

Review in The Lancet. Infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 243 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
243citing papers in PubMed, 5 pooled it
58.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04362176 phase3completednot on this mapstarted 2020, after this paper: background citation

Passive Immunity Trial for Our Nation (PassItOn)

TypeinterventionalSponsorVanderbilt University Medical CenterRan2020 to 2021Enrolled974ConditionsCOVID-19, Coronavirus, SARS-CoV-2Armspathogen reduced SARS-CoV-2 convalescent plasma, Placebo
NCT04372628 phase2completednot on this mapstarted 2020, after this paper: background citation

Trial of Early Therapies During Non-hospitalized Outpatient Window (TREAT NOW) for COVID-19

TypeinterventionalSponsorVanderbilt University Medical CenterRan2020 to 2022Enrolled452ConditionsCOVID-19ArmsLopinavir/Ritonavir 400 mg/100 mg, Placebo
3 · Its place in the literature

Who cites it

243 citing papers in PubMed, 5 syntheses or guidelines pooled it, 449 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Review
  8. Decoding antibody response to MERS-CoV in wild dromedary camels.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  9. Review
  10. Observational
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

183 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 6 institutions in 5 countries.

David S HuiDepartment of Medicine and Therapeutics and Stanley Ho Centre for Emerging Infectious Diseases, The Chinese University of Hong Kong, Shatin, Hong Kong, Special Administration Region, China.
Esam I AzharSpecial Infectious Agents Unit, King Fahd Medical Research Centre and Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia.
Yae-Jean KimDivision of Infectious Diseases, Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Ziad A MemishCollege of Medicine, Alfaisal University, Riyadh, Saudi Arabia; Division of Infectious Diseases, Department of Internal Medicine, Prince Mohammed Bin Abdulaziz Hospital, Ministry of Health, Riyadh, Saudi Arabia; Rollins School of Public Health, Emory University, Atlanta, GA, USA.
Myoung-Don OhDepartment of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea.
Alimuddin ZumlaCentre for Clinical Microbiology, Division of Infection and Immunity, University College London, London, UK; NIHR Biomedical Research Centre, University College London Hospitals, London, UK. Electronic address: a.zumla@ucl.ac.uk.
Alfaisal University · SAChinese University of Hong Kong · CNKing Abdulaziz University · SASamsung Medical Center · KRSeoul National University · KRUniversity College London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Middle East respiratory syndrome coronavirus (MERS-CoV) is a lethal zoonosis that causes death in 35·7% of cases. As of Feb 28, 2018, 2182 cases of MERS-CoV infection (with 779 deaths) in 27 countries were reported to WHO worldwide, with most being reported in Saudi Arabia (1807 cases with 705 deaths). MERS-CoV features prominently in the WHO blueprint list of priority pathogens that threaten global health security. Although primary transmission of MERS-CoV to human beings is linked to exposure to dromedary camels (Camelus dromedarius), the exact mode by which MERS-CoV infection is acquired remains undefined. Up to 50% of MERS-CoV cases in Saudi Arabia have been classified as secondary, occurring from human-to-human transmission through contact with asymptomatic or symptomatic individuals infected with MERS-CoV. Hospital outbreaks of MERS-CoV are a hallmark of MERS-CoV infection. The clinical features associated with MERS-CoV infection are not MERS-specific and are similar to other respiratory tract infections. Thus, the diagnosis of MERS can easily be missed, unless the doctor or health-care worker has a high degree of clinical awareness and the patient undergoes specific testing for MERS-CoV. The largest outbreak of MERS-CoV outside the Arabian Peninsula occurred in South Korea in May, 2015, resulting in 186 cases with 38 deaths. This outbreak was caused by a traveller with undiagnosed MERS-CoV infection who became ill after returning to Seoul from a trip to the Middle East. The traveller visited several health facilities in South Korea, transmitting the virus to many other individuals long before a diagnosis was made. With 10 million pilgrims visiting Saudi Arabia each year from 182 countries, watchful surveillance by public health systems, and a high degree of clinical awareness of the possibility of MERS-CoV infection is essential. In this Review, we provide a comprehensive update and synthesis of the latest available data on the epidemiology, determinants, and risk factors of primary, household, and nosocomial transmission of MERS-CoV, and suggest measures to reduce risk of transmission.

Indexed as

Cross InfectionDisease Transmission, InfectiousFamily CharacteristicsAnimalsCamelusCoronavirus InfectionsDisease OutbreaksGlobal HealthHumansMiddle East Respiratory Syndrome CoronavirusRisk FactorsSaudi ArabiaZoonoses

Identifiers

PMID29680581
PMCPMC7164784
OpenAlexW2801339009

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.